1. Cyhoeddwyd

   The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

   Marson, A., Burnside, G., Appleton, R., Smith, D., Leach, J. P., Sills, G., Tudor-Smith, C., Plumpton, C., Hughes, D., Williamson, P., Baker, G. A., Balabanova, S., Taylor, C., Brown, R., Hindley, D., Howell, S., Maguire, M., Mohanraj, R. & Smith, P. E., 10 Ebr 2021, Yn: The Lancet. 397, 10282, t. 1363-1374

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

2. Cyhoeddwyd

   Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs

   Marson, A. G., Burnside, G., Appleton, R., Smith, D., Leach, J. P., Sills, G., Tudor-Smith, C., Plumpton, C., Hughes, D., Williamson, P. R., Baker, G., Balabanova, S., Taylor, C., Brown, R., Hindley, D., Howell, S., Maguire, M., Mohanraj, R. & Smith, P. E., Rhag 2021, Yn: Health Technology Assessment. 25, 75, 162 t.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   Predictors of Self-Reported Adherence to Antihypertensive Medicines: A Multinational, Cross-Sectional Survey

   Morrison, V. L., Holmes, E. A., Parveen, S., Plumpton, C. O., Clyne, W., De Geest, S., Dobbels, F., Vrijens, B., Kardas, P. & Hughes, D., Maw 2015, Yn: Value in Health. 18, 2, t. 206-216

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

4. Cyhoeddwyd

   Cost effectiveness of pharmacogenetic screening prior to initiation of carbamazepine treatment for epilepsy

   Plumpton, C. O., Yip, V., Alfirevic, A., Marson, A., Pirmohamed, M. & Hughes, D., Tach 2013, Yn: Value in Health. 16, 7, t. A624-A624

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

5. Cyhoeddwyd

   What are the experiences of cancer care in gay, lesbian and bisexual patients, and how do these differ from heterosexual cancer patients?

   Plumpton, C. O., Neal, R. D., Hulbert-Williams, N., McHugh, R., Semlyen, J., Flowers, P., Storey, L., Ream, E. & Neal, R., 28 Ebr 2015, Yn: Psycho-Oncology. 24, S1, t. 2-3

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

6. Cyhoeddwyd

   Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout

   Plumpton, C., Alfirevic, A., Pirmohamed, M. & Hughes, D., 1 Hyd 2017, Yn: Rheumatology. 56, 10, t. 1729-1739

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   Cost-effectiveness of HLA-B*15:02 screening in Malaysia

   Plumpton, C. & Hughes, D., Hyd 2017, Yn: British Journal of Dermatology. 177, 4, t. 904-905

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Sylw/Dadl

8. Cyhoeddwyd

   Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy

   Plumpton, C., Yip, V. L. M., Alfirevic, A., Marson, A. G., Pirmohamed, M. & Hughes, D., Ebr 2015, Yn: Epilepsia.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

9. Cyhoeddwyd

   Cost-Effectiveness Of PET/CT In Pre-Operative Staging Of Pancreatic Cancer: An Economic Evaluation Of The PET-PANC Cohort Study

   Plumpton, C., Ghaneh, P., Lloyd-Williams, H., Yeo, S. T. & Edwards, R., Hyd 2017, Yn: Value in Health. 20, 9, t. A589

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl

10. Cyhoeddwyd

    Cost-effectiveness of panel tests for multiple pharmacogenes associated with adverse drug reactions: An evaluation framework

    Plumpton, C., Pirmohamed, M. & Hughes, D., Meh 2019, Yn: Clinical Pharmacology and Therapeutics. 105, 6, t. 1429-1438

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid